ArticleBMJ open respiratory research2021
Economic burden of asthma in Singapore.
Article in BMJ open respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Health loss and economic burden of asthma in China: a qualitative review based on existing literature.Archives of public health = Archives belges de sante publique · 2025Pooled it
- Projecting the 20-year healthcare resource burden of asthma and COPD multimorbidity: insights from Singapore for integrated chronic respiratory care in South-East Asia.NPJ primary care respiratory medicine · 2026Article
- Societal and personal financial burden of severe asthma and impact of biologic therapy: a 19-year nationwide cost analysis.BMJ open respiratory research · 2026Article
- Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective.PloS one · 2026Article
- Economic burden of asthma multimorbidity in Singapore: Shadow costs of steroid use.The World Allergy Organization journal · 2025Article
- Guideline-based asthma treatment in Asia: Insights from a robust time-in-state model.The journal of allergy and clinical immunology. Global · 2025Article
- Observational
- Global, regional, national burden of asthma from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021.EClinicalMedicine · 2025Article
- Methodological considerations for estimating indirect costs in children and adolescents with chronic conditions: a scoping review.BMC pediatrics · 2025Article
- Forecasting Hospitalization for Adult Asthma Patients in Emergency Departments Based on Multiple Environmental and Clinical Factors.Journal of asthma and allergy · 2025Article
- Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population.NPJ primary care respiratory medicine · 2024Article
- SABA prescriptions and asthma management practices in Singapore: results from a cross-sectional, observational SABINA III study.BMJ open · 2024Observational
- Patient Characteristics, Management, and Outcomes of Adult Asthma in a Singapore Population: Data from the SDG-CARE Asthma Registry.Pragmatic and observational research · 2024Article
- The increasing burden of asthma acute care in Singapore: an update on 15-year population-level evidence.BMC pulmonary medicine · 2023Article
- Medical resource utilization and the associated costs of asthma in China: a 1-year retrospective study.BMC pulmonary medicine · 2023Article
- Innovation workshop using design thinking framework and involving stakeholders to co-create ideas for management of asthma.NPJ primary care respiratory medicine · 2023Article
- Beyond direct costs: individual and societal financial burden of asthma in young adults in a Danish nationwide study.BMJ open respiratory research · 2023Article
- The Impact of Obesity in Saudi Arabia: Healthcare Resource Use and Costs Associated with Obesity-Related Complications.Advances in therapy · 2023Article
- Impact of Guideline-Based Asthma Treatment on Health Services Use in Singapore Before and During COVID-19 Outbreak.Journal of asthma and allergy · 2023Article
- Burden and unmet needs in asthma care in the Asia-Pacific region.Public health challenges · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveUp-to-date economic burden of asthma in Singapore is currently unknown.
methodsWe quantify the per capita and total annual costs of asthma for adults and children by level of symptom control (uncontrolled, partly controlled, and well controlled) via a cross-sectional online survey administered to a national web panel. Participants were asked about healthcare utilisation, days missed from work, and reduced productivity due to their symptoms. These values were then monetised and multiplied by prevalence estimates of adult and child asthmatics to generate total costs.
resultsA total of 300 adults and 221 parents of children with asthma were included in analysis. The total annual cost of adult asthma was estimated to be SGD 1.74 billion (US$1.25 billion) with 42% coming from the uncontrolled group, 45% from the partly controlled group, and 13% from the well-controlled group. For children, the total cost is SGD 0.35 billion (US$0.25 billion), with 64%, 26% and 10% coming from each group respectively. Combined, the annual economic burden of asthma in Singapore is SGD 2.09 billion (US$1.50 billion) with 79% due to productivity losses.
conclusionPoorly controlled asthma imposes a significant economic burden. Therefore, better control of disease has the potential to generate not only health improvements, but also medical expenditure savings and productivity gains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.